What is it about?

Sepsis is a life-threatening response to infection, and many patients who survive the hospital stay still die in the following months. Predicting who is at highest risk is difficult. We measured several blood markers - including C-reactive protein, procalcitonin, lactate, interleukin-6, pro-adrenomedullin and IGFBP-3, a protein involved in growth and cell survival - at admission in 139 patients with confirmed sepsis in the internal medicine department of the Trieste University Hospital. Age, organ failure severity (SOFA score), infection in more than one site and low IGFBP-3 independently predicted death within one year. Patients with low IGFBP-3 had lower body temperature and fewer lymphocytes, signs of a weakened immune response, and higher mortality. Adding IGFBP-3 to a clinical model improved prediction of death at 60, 90 and 365 days.

Featured Image

Why is it important?

Most sepsis biomarkers reflect inflammation, but long-term death is often driven by immune suppression. IGFBP-3, a simple blood test, may capture this side of the disease and help identify, at admission, patients who need closer follow-up or future immune-supportive treatments. Validation in larger cohorts could turn it into a practical prognostic tool.

Perspectives

Sepsis does not end at hospital discharge, and internal medicine wards care for many of the frailest septic patients. I appreciate this line of research by Filippo Mearelli and the Clinica Medica in Trieste, which looks at the immune and metabolic consequences of sepsis and could help personalize follow-up of survivors.

Professor Stefano Di Bella
Universita degli Studi di Trieste

Read the Original

This page is a summary of: Lower Initial Insulin-like Growth Factor-Binding Protein-3 Concentrations May Reflect Immune Suppression and Predict Increased Risk of Sepsis-Related Mortality, International Journal of Molecular Sciences, July 2025, MDPI AG,
DOI: 10.3390/ijms26146549.
You can read the full text:

Read

Contributors

The following have contributed to this page